Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
复制标题
DOI:
10.1016/j.ccell.2020.08.004
复制
发表时间:
2020-12-14
期刊:
影响因子:
50.3
通讯作者:
O'Hara MH
中科院分区:
文献类型:
--
作者:
Bear AS;Vonderheide RH;O'Hara MH
Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types. Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression from the earliest stages of tumor inception to subvert adaptive T-cell immunity. Single-agent immune modulators have thus far proven clinically ineffective, and multi-modal therapies targeting mechanisms of immunotherapy resistance are likely needed. Herein, we review novel immunotherapy strategies currently under investigation to (1) confer antigen specificity, (2) enhance T-cell effector function and (3) neutralize immunosuppressive elements within the tumor microenvironment that may be rationally combined to untangle the web of immune resistance in PDA and other tumors.
登录
查看更多内容
影响因子:
8.8
作者:
通讯作者:
--
影响因子:
8.8
作者:
Candido JB;Morton JP;Bailey P;Campbell AD;Karim SA;Jamieson T;Lapienyte L;Gopinathan A;Clark W;McGhee EJ;Wang J;Escorcio-Correia M;Zollinger R;Roshani R;Drew L;Rishi L;Arkell R;Evans TRJ;Nixon C;Jodrell DI;Wilkinson RW;Biankin AV;Barry ST;Balkwill FR;Sansom OJ
通讯作者:
Sansom OJ
影响因子:
15.9
作者:
Blair, Alex B.;Kleponis, Jennifer;Zheng, Lei
通讯作者:
Zheng, Lei
影响因子:
29.4
作者:
Beatty GL;O'Hara MH;Lacey SF;Torigian DA;Nazimuddin F;Chen F;Kulikovskaya IM;Soulen MC;McGarvey M;Nelson AM;Gladney WL;Levine BL;Melenhorst JJ;Plesa G;June CH
通讯作者:
June CH
影响因子:
82.9
作者:
Binnewies M;Roberts EW;Kersten K;Chan V;Fearon DF;Merad M;Coussens LM;Gabrilovich DI;Ostrand-Rosenberg S;Hedrick CC;Vonderheide RH;Pittet MJ;Jain RK;Zou W;Howcroft TK;Woodhouse EC;Weinberg RA;Krummel MF
通讯作者:
Krummel MF